Storing and travelling with a GLP-1

Unopened, all four labels say the same thing: a refrigerator between 36°F and 46°F (2°C to 8°C), in the original carton, not pressed against the cooling element, and never frozen. What differs between them is how long the product may sit at room temperature, and those allowances range from 21 days to 56 days.

That single difference is where most of the confusion comes from, because the number people remember is usually from a different product than the one in their fridge. Here is each label’s own figure, followed by what TSA’s published rules say about flying with it.

The room temperature clock is the part that differs

Every figure in this table is from the product’s own US prescribing information. The upper limit is 86°F (30°C) in all four.

Product	Unopened	Room temperature allowance	Discard trigger
Ozempic multi-dose pen	Fridge 36 to 46°F until the expiration date	56 days at 59 to 86°F, or keep refrigerated	56 days after first use, even if product remains
Ozempic single-dose prefilled syringe	Fridge 36 to 46°F	Up to 28 days at 46 to 86°F if needed	After use, or after the 28 days
Wegovy single-dose pen or syringe	Fridge 36 to 46°F	Up to 28 days at 46 to 86°F, before cap removal, in the carton	After use, 28 days out of the fridge, freezing, light or above 86°F
Wegovy FlexTouch pen (4 doses of 2.4 mg)	Fridge 36 to 46°F	56 days at 59 to 86°F after first use, or keep refrigerated	56 days out of the fridge, freezing, light or above 86°F
Mounjaro or Zepbound single-dose pen or vial	Fridge 36 to 46°F	Up to a total of 21 days, up to 86°F	A total of 21 days at room temperature
Mounjaro or Zepbound multi-dose vial or KwikPen	Fridge until expiry, or 30 days if kept at room temperature	Fridge or room temperature up to 86°F	30 days at room temperature, 30 days after first use, or 4 weekly doses

Two details in that table catch people out. The Mounjaro and Zepbound allowance is a total of 21 days, so it accumulates across separate trips out of the fridge rather than resetting each time. And the Wegovy single-dose allowance applies before the cap is removed, which makes it a shelf-life window rather than an in-use one, since the pen is used once and discarded.

The multi-dose devices run three clocks at once

The tirzepatide multi-dose vial and the single-patient-use KwikPen each hold four weekly doses, so they are in use for a month by design. Their labels impose three separate limits and whichever arrives first governs: 30 days at room temperature, 30 days after first use, or four weekly doses taken, even if medicine is left in the device.

The four-dose limit is the one that is easy to miss, because it is not a time at all. The device can be inside both date limits and still be finished. These are also the presentations where the strength per millilitre differs from the single-dose vials, which matters for anyone drawing a dose by volume rather than using the device, as set out in tirzepatide dosing in units.

Freezing and light are absolute, not clocks

Unlike the temperature allowances, these are stated without a duration. All four labels say do not freeze and do not use the product if it has been frozen. Ozempic’s label adds not to store pens directly next to the cooling element, which is the part of a domestic fridge most likely to drop below freezing.

Light is handled the same way. Mounjaro and Zepbound say to store the product in the original carton to protect it from light. Wegovy’s injection must be kept in the original carton until administration, and its patient information lists exposure to light alongside freezing and heat as a reason to throw a pen away. The practical consequence is that the carton is part of the storage instruction, not packaging to discard on the way home from the pharmacy.

What TSA’s rules actually say

The security side is more permissive than most people expect, and the published rules are short:

• Quantity: you may bring medically necessary liquids, medications and creams in excess of 3.4 ounces or 100 millilitres in a carry-on bag. Larger amounts are allowed in reasonable quantities for the trip.
• Screening: remove them from the carry-on bag to be screened separately from everything else, and declare medically necessary liquids to officers at the checkpoint for inspection.
• Labelling: clear labelling is recommended to make screening easier, not required.
• Cooling: ice packs, freezer packs, gel packs and similar accessories may be presented frozen, partially frozen or melted when they are keeping a medically necessary item cool. The rule that frozen liquids must be solid at screening does not apply to them.
• Sharps: unused syringes are allowed in carry-on and checked bags when accompanied by injectable medication, and must be declared at the checkpoint for inspection. Used ones are allowed in a sharps or similar hard-surface container.
• The caveat: TSA states that the final decision on whether any item passes the checkpoint rests with the officer at the checkpoint.

None of that forbids checked luggage. The reason to keep these products in the cabin is the label’s 36°F to 86°F range, which an aircraft hold is not controlled to, plus the obvious point that a bag in the hold cannot be checked on or retrieved if a connection goes wrong.

Cars, beaches and the 86°F ceiling

86°F is a low ceiling in practice. A car interior parked in summer sun passes it easily, and a checked bag standing on an airport apron can too. The labels do not offer a grace period above that temperature: Wegovy’s patient information says to throw away a pen that has been exposed to temperatures above 86°F, full stop.

The lower bound matters as much on the road. A cooler packed directly against ice or a frozen gel pack can take a pen below freezing, which the labels treat as disqualifying rather than as a matter of degree. An insulating layer between the pen and the cold source is what keeps the product inside the 36°F floor.

What the labels do not settle

Two common travel questions are outside the storage sections entirely. The first is the weekly injection day across time zones, which is a dosing-schedule question for the prescriber rather than a storage one, and the labels differ on how much flexibility they describe. The second is whether a specific pen that got warm or was left out too long is still usable.

On the second, the labels give discard rules but no way to assess a particular pen, and appearance is not a test: these solutions are described as clear and colourless, so a product that looks normal can still be outside its allowance. The dispensing pharmacist is the right person to ask, and they can usually check what was dispensed and when. Where it ends up being injected is a separate matter, covered in GLP-1 injection sites, and what the first weeks look like generally is in your first month on a GLP-1.

FAQ

Sources

• OZEMPIC (semaglutide) injection, US prescribing information, Novo Nordisk. Section 16.2 and patient information: storage of pens and prefilled syringes.
• WEGOVY (semaglutide) injection, US prescribing information, Novo Nordisk. Section 16.2 and patient information: single-dose pen, single-dose syringe and FlexTouch storage.
• MOUNJARO (tirzepatide) injection, US prescribing information, Eli Lilly and Company. Section 16.2 and patient information: single-dose and multi-dose storage.
• ZEPBOUND (tirzepatide) injection, US prescribing information, Eli Lilly and Company. Section 16.2 and patient information: single-dose and multi-dose storage.
• Transportation Security Administration. Travelling with medication: medically necessary liquids, screening and labelling guidance.
• Transportation Security Administration. What Can I Bring: gel ice packs and medically necessary cooling accessories.

This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.